by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
AusBioPEOPLE Volume 19 • Number 3 • October 2009 Australasian BioTechnology 77 RxCON RxCON Consulting is a boutique consulting company that provides expertise services to bio-pharmaceutical companies on drug development. Our consultants are experienced professionals in their field, with international experiences in USA, Europe, Australia/New Zealand and Asia -- China, Korea, Japan, Singapore, Thailand, Malaysia, Taiwan, Hong Kong and Phillipines. Our aim is to proactively work with our clients to find the best possible way to achieve project objectives. Our services include: Clinical • ~ Project Management ~ Study Set-up: including feasibility and site selection, ethics submission, contract negotiation etc ~ Clinical Monitoring ~ Clinical Study Report writing Regulatory • ~ Regulatory submissions for regulatory approval ~ Product registration, orphan drug designation Quality Assurance • ~ Quality Management System set up and improvement, including SOP and working instruction ~ Audit: project audit, facility audit, lab audit and vendor audit Training • ~ in-house training program on GCP, project management Website: www.rxcon.com.au Email: Info@rxcon.com.au Telephone: +61 02 9922 6759 Changing lives through regenerative medicine Australian Biotechnologies is primarily focused on the manufacture of innovative human tissue-based products to repair and promote natural healing of human bone and other human tissues. We introduce advanced processing techniques by partnering with leading international organisations so as to allow Australian Surgeons access to the most current technology for human tissue based products. We hold an exclusive licence for a Super Critical Fluid Tissue Sterilisation technology for the Asia Pacific and ANZ region. For more information, contact; Tom Mende, CEO Email: TomMende@ausbiotech.com.au DDI: +61 402 063 863 Web: www.ausbiotech.com.au Shire Shire opened its Australian office in May 2008, and currently has three products on the local market -- Replagal for Fabry Disease, Fosrenol for hyperphosphataemia in renal failure, and Agrylin for essential thrombocytosis. Shire is a niche global biopharmaceutical company specialising in haematology, gastro-intestinal disorders, renal diseases, ADHD, and rare Orphan genetic disorders such as Fabry Disease, Hunters Syndrome, Gauchers Disease, Pompe Disease, Sanfilippo Syndrome, Hereditary Angio-Oedema, and Metachromatic Leukodystrophy, amongst others. Shire has its head office in Basingstoke, England, is the third largest biopharmaceutical company in the UK, has around 4,000 staff worldwide, and annual sales of over USD $3B. Please contact: Dr Dominic Barnes, Vice President and General Manager firstname.lastname@example.org or telephone 02 88757771 Managing and developing investments in the life science sector pharmaBank is a biotech development fund with the major objectives to identify, invest in, manage and commercialise opportunities in the field of life sciences. pharmaBank assists in the development of technologies in the areas of therapeutics, devices and diagnostics to realise significant investment returns. It invests in life science technologies together with private equity investors. pharmaBank does not invest in projects at the 'discovery' stage. Instead, it identifies and invests in projects that are close to or have already entered human clinical trials. Strategically, these projects must address large global markets for which a strong intellectual property position has been secured. For further information: Damien W. Millen | Chief Executive Officer pharmaBank Pty Ltd ANU House, L10, 52 Collins Street, Melbourne VIC 3000, AUSTRALIA P: +61 3 9663 3330 F: +61 3 9663 3360 M: +61 (0)410 649 619 email@example.com www.pharmabank.com.au